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Edited by Judit Ova´diAbstract Synphilin-1 is an a-synuclein binding protein that is
involved in the pathogenesis of Parkinson’s disease. The present
study investigated the phospholipid-binding capacity of Synphi-
lin-1. The C-terminus of Synphilin-1 was found to selectively
bind to acidic phospholipids, including phosphatidic acid, phos-
phatidylserine, and phosphatidylglycerol, but not to naturally
charged phospholipids. Synphilin-1 was targeted to cytoplasmic
lipid droplets in mammalian cells. The amino acid sequence
610–640 was found to represent the primary determinant site
for phospholipid binding. Moreover, the R621C mutation identi-
ﬁed in Parkinson’s disease abolished Synphilin-1 association
with lipid droplets. The lipophilicity of Synphilin-1 might prove
relevant to its physiologic function.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Parkinson’s disease represents the second most common
neurodegenerative disorder, pathologically characterized by
loss of dopaminergic neurons in the substantia nigra pars com-
pacta and appearance of Lewy bodies in remaining neurons
[1]. Autosomal dominant Parkinson’s disease, i.e. PARK1
and PARK4, is caused by missense mutations and triplication
of the gene for a-synuclein, one of the main components of
Lewy bodies [2]. Several studies suggest association of a-synuc-
lein with phospholipids and lipid membranes [3]. a-Synuclein is
involved in vesicle traﬃcking and lipid droplet accumulation
[4].
Synphilin-1, an a-synuclein-interacting protein, is a compo-
nent of the core region of Lewy bodies. The mutation in the
Synphilin-1 gene leading to a substitution from arginine (R)
to cysteine (C) at position 621 (R621C) has been identiﬁed
in Parkinson’s disease [5]. Synphilin-1 contains six ankyrin
repeats, a coiled-coil domain, and a well conserved regionAbbreviations: CL, cardiolipin; GST, glutathione S-transferase; LC,
lysophosphatidylcholine; PA, phosphatidic acid; PC, phosphatidyl-
choline; PE, phosphatidylethanolamine; PG, phosphatidylglycerol; PI,
phsophatidylinositol; PS, phosphatidylserine; SM, sphingomyeline;
MLVs, multilamellar vesicles
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doi:10.1016/j.febslet.2006.07.019(amino acids (aa) 612–689) of unknown function [5]. Lipid
fractions of brain extracts contain Synphilin-1 [6–8]. Synphi-
lin-1 is predominantly expressed in neurons, where it localizes
to the cytoplasm as well as presynaptic nerve terminals, and
associates with synaptic vesicles. Accordingly, intracellular
localization of Synphilin-1 is similar to that of a-synuclein.
The present study investigated the binding capacity of Synphi-
lin-1 with phospholipids and lipid membranes.2. Materials and methods
2.1. Phospholipids and reagents
Lysophosphatidylcholine (LC), sphingomyeline (SM), phosphatidyl-
choline (PC), phosphatidic acid (PA), phsophatidylinositol (PI), phos-
phatidylserine (PS), cardiolipin (CL), phosphatidylethanolamine (PE),
phosphatidylglycerol (PG), and dioleoylphosphocholine were obtained
from Sigma. 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine,
1-palmitoyl-2- oleoyl-sn-glycero-3-phosphate, 1-palmitoyl-2-oleoyl-sn-
glycero-3-[phospho-L-serine] were purchased from Avanti Polar Lipid.
Oleic acid, fatty acid-free BSA, and oil red O were purchased from
Sigma.
2.2. Vectors and preparation of GST-fusion proteins
The coding region of human Synphilin-1 cDNAwas subcloned into a
pcDNA3 vector (BD Biosciences) in frame with the HA tag sequence
(pcDNA3-HA-Synphilin-1), as previously described [9]. The R621C
point mutation of Synphilin-1 was generated using a transformer site-
directed mutagenesis kit (BD Biosciences) with the following synthetic
oligonucleotide: 5 0-CTG ATA AAA TCT TAT GCC AGT TAT TGG
G-3 0. The mutation was conﬁrmed by DNA sequencing. DNA frag-
ments obtained from PCR were subcloned into a pcDNA3 vector in
frame with the HA tag sequence (pcDNA3-HA-Synphilin-1 R621C).
To generate Synphilin-1 proteins fused with glutathione S-transfer-
ase (GST) at the N-terminus, corresponding cDNA fragments for var-
ious truncations of Synphilin-1, including the N-terminus (aa 1–202,
GST-Syp-N1), the middle N-terminus plus the ankyrin repeats from
1–3 (aa 87–458, GST-Syp-N2), the ankyrin repeats 1–4 plus the
coiled-coil domain (aa 349–617, GST-Syp-ANK), the ankyrin repeats
5–6 plus the C-terminus (aa 611–919, GST-Syp-C), and serial C-termi-
nal truncations (aa 610–675, GST-Syp-C1; aa 641–730, GST-Syp-C2;
aa 706–806, GST-Syp-C3; aa 771–880, GST-Syp-C4; and aa 851–
919, GST-Syp-C5) were subcloned into a pGEX6P-1 vector (Amer-
sham), as previously described [9]. The sequences of all constructs were
conﬁrmed by DNA sequencing. GST-fusion proteins were produced in
Escherichia coli BL21 via isopropyl-b-D-thiogalactopyranoside (Sigma)
induction and puriﬁed using glutathione–sepharose 4B (Amersham), as
previously described [9–14].
2.3. Cell culture and immunoﬂuorescent staining
COS7 cells were obtained from the American Type Culture Collec-
tion and grown in Dulbecco’s modiﬁed Eagle’s medium with 10% fetal
calf serum. Cells seeded and grown on glass coverslips in the medium
were transfected with pcDNA3-HA-Synphilin-1 or pcDNA3-HA-Syn-
philin-1 R621C using FuGENE 6 (Roche), as previously describedblished by Elsevier B.V. All rights reserved.
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presence of 600 lM oleic acid and 100 lM fatty acid-free BSA in the
medium for 14 h to induce cytoplasmic lipid droplets. Adherent cells
on the glass coverslips were ﬁxed, permeabilized, and immunostained
using an anti-HA antibody (Sigma), followed by the Alexa Fluor
488 anti-rabbit IgG antibody (Invitrogen), as previously described
[12]. Cells on the same glass coverslips were incubated with the oil
red O solution (3 mg/ml in 36% triethylphosphate) for 0.5 h to visualize
cytoplasmic lipid droplets. Preparations were examined with a Zeiss
LSM510 confocal microscope.
2.4. Protein–lipid overlay assay
A protein–lipid overlay assay was performed using the GST-fusion
proteins, as previously described [15]. To make a membrane pre-spot-
ted with a concentration gradient of phospholipids (the membrane
phospholipid array), the phospholipid solutions, each at 12.5 lg/ll
(1·), were serially diluted from 2-fold (2·) up to 32-fold (32·) with
chloroform/methanol/distilled water (1:2:0.8). Each 1 ll of serial dilu-
tions of phospholipids was spotted onto a nitrocellulose membrane
(Schleicher and Schuell) and dried to allow each spot to contain the
following dose of phospholipid: 12.5 lg/1· spot, 6.25 lg/2· spot,
3.13 lg/4· spot, 1.56 lg/8· spot, 0.78 lg/16· spot, and 0.39 lg/32·
spot.
For a protein–lipid overlay assay, the membrane phospholipid array
was blocked with TBS-T (50 mM Tris–HCl (pH 7.5), 150 mM NaCl,
and 0.1% Tween 20) plus 3% (w/v) fatty acid-free BSA for 1 h at roomFig. 1. Association of Synphilin-1 protein with phospholipids. (A) Schemati
(GST)-fusion proteins utilized for the assay. A series of truncations in the
(ANK1-6) or the coiled-coil (CC) domain, was fused with GST at the N-ter
Coomassie staining. Molecular mass markers are indicated on the left. (B)
array, serial dilutions of phospholipids, including lysophosphatidylcholine (L
(PA), phsophatidylinositol (PI), phosphatidylserine (PS), cardiolipin (CL),
spotted onto a nitrocellulose membrane to allow each spot to contain the foll
8· spot, 0.78 lg/16· spot, and 0.39 lg/32· spot. The membrane phospholipid
vehicle (none) and bound proteins were detected by immunoblotting with antemperature, followed by incubation with GST-fusion proteins (2 lg/
ml) or proteins in TBS-T plus 3% (w/v) fatty acid-free BSA at 4 C
overnight. After the membrane was washed 6 times with TBS-T, at
5 min per washing, GST-fusion proteins bound to phospholipids spot-
ted on the membrane were analyzed with immunoblotting with an anti-
GST monoclonal antibody (1:1000). The blots were developed using
enhanced chemiluminescence reagents (Amersham).
Alternatively, COS7 cells seeded on a 6 cm-dish (1.5 · 106 cells per
dish) were transfected with empty pcDNA3-HA vectors, pcDNA3-
HA-Synphilin-1 or pcDNA3-HA-Synphilin-1 R621 C. After 24 h post
transfection, cells were washed with ice-cold PBS and lysed in ice-cold
lysis buﬀer (50 mM Tris–HCl, pH 7.4, 150 mM NaCl, 1 mM EGTA,
and protease inhibitors) and centrifuged. After the lysate protein con-
tents were measured using a protein assay kit (Bio-Rad, Hercules, CA,
USA), the lysate proteins were diluted at a concentration of 2 lg/ml in
TBS-T plus 3% (w/v) fatty acid-free BSA, and subjected to a protein–
lipid overlay assay using the membrane phospholipid array in the same
manner.
2.5. Binding of Synphilin-1 to synthetic phospholipid vesicles
1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanolamine, 1-palmi-
toyl-2-oleoyl-sn-glycero-3-phosphate, or 1-palmitoyl-2-oleoyl-sn-gly-
cero-3-[phospho-L-serine] was each mixed with dioleoylphospho-
choline (molar ratio 1:1) in chloroform. The lipid was deposited as a
ﬁlm on the wall of a glass test tube by solvent evaporation with nitro-
gen stream, followed by pumping for 2 h under vacuum. The resultingc representation of the primary structures of glutathione S-transferase
conserved region of Synphilin-1 (Syp), including six ankyrin repeats
minus. (right) GST-fusion protein used for the assay was detected by
Protein–lipid overlay assay. To generate the membrane phospholipid
C), sphingomyeline (SM), phosphatidylcholine (PC), phosphatidic acid
phosphatidylethanolamine (PE), and phosphatidylglycerol (PG), were
owing doses: 12.5 lg/1· spot, 6.25 lg/2· spot, 3.13 lg/4· spot, 1.56 lg/
arrays were incubated with 2 lg/ml of GST-fusion proteins (input) or
anti-GST antibody.
Fig. 2. Binding of Synphilin-1 with phospholipid-containing vesicles.
Multilamellar vesicles (MLVs) containing phosphatidic acid (PA),
phosphatidylserine (PS), and phosphatidylethanolamine (PE) were
prepared. Incubations with various GST-fusion Synphilin-1 proteins
or GST alone (input) were performed with MLVs or vehicle (N),
followed by ultracentrifugation. Proteins bound to MLVs in the pellet,
as well as input proteins, were analyzed by immunoblotting with an
anti-GST antibody.
T. Takahashi et al. / FEBS Letters 580 (2006) 4479–4484 4481lipid ﬁlm was re-hydrated in HBS (10 mM HEPES–NaOH (pH 7.4)
and 150 mM NaCl) followed by vortexing for 20 min to form multila-
mellar vesicles (MLVs). MLVs were mixed with GST-fusion proteinsFig. 3. The C-terminus of Synphilin-1 associates with phospholipids. (A) Sche
proteins utilized for the assay. The C-terminus of Syp (GST-Syp-C in Fig. 1A
GST. (right) GST-fusion protein used for the assay was detected by Coom
Protein–lipid overlay assay. The membrane phospholipid arrays were incubat
Fig. 1. GST-fusion proteins bound to phospholipids spotted on the membra(mass ratio 1:20) in TE (10 mM Tris–HCl (pH 8.0) and 1 mM EDTA)
and incubated for 2 h, followed by ultracentrifugation at 164000 · g
for 0.5 h. The pellet of MLVs was washed ﬁve times with TE and dis-
solved in sample buﬀer. GST-fusion proteins bound to MLVs were
analyzed by immunoblotting with an anti-GST antibody (Sigma).3. Results and discussion
3.1. The C-terminus of Synphilin-1 has a speciﬁc capacity to
bind to acidic phospholipids
To investigate whether or not Synphilin-1 interacts with
phospholipids in cells, nine diﬀerent biologically abundant
phospholipids found in intracellular membranes, that is LC,
SM, PC, PA, PI, PS, CL, PE, and PG were chosen for the as-
say. A protein–lipid overlay assay was performed using the
membrane phospholipid array with recombinant GST-fusion
proteins containing various truncations of Synphilin-1
(Fig. 1A). The binding aﬃnity of proteins for phospholipids
was also evaluated at six dilution levels from 1· to 32·.
The PA-binding aﬃnity of GST alone, as well as GST-Syp-N1,
-N2, or -ANK was only detected at the 1· to 2· dilution level
(Fig. 1), suggesting that such binding is non-speciﬁc. In con-
trast, the binding of GST-Syp-C to PA was detected in amatic representation of the constructs of GST-fusion Synphilin-1 (Syp)
) was divided into ﬁve parts and a series of truncations was fused with
assie staining. Molecular mass markers are indicated on the left. (B)
ed with GST-fusion proteins (2 lg/ml, input) in the same manner as in
ne were analyzed by immunoblotting with an anti-GST antibody.
Fig. 4. Phospholipid-binding property of Synphilin-1. (A) A protein–lipid overlay assay using COS7 cells transfected with empty pcDNA3-HA
vectors (Cont), pcDNA3-HA-Synphilin-1 wild type (WT), or pcDNA3-HA-Synphilin-1 R621C (R621C) was performed. (left upper) Wild type and
mutant HA-tagged Synphilin-1 (HA-Synphilin-1) proteins in lysates proteins from transfected cells were analyzed by immunoblotting with an anti-
HA antibody. 0.2 lg of cell lysate protein was loaded per each lane. (left lower and right) A protein–lipid overlay assay. The cell lysate proteins were
diluted at a concentration of 2 lg/ml in TBS-T plus 3% (w/v) fatty acid-free BSA, and subjected to a protein–lipid overlay assay using the membrane
phospholipid array. HA-Synphilin-1 proteins bound to phospholipids were analyzed by immunoblotting with an anti-HA antibody. (B) Wild type
Synphilin-1 localization around lipid droplets in mammalian cells. COS7 cells transfected with expression vectors for wild type (WT) or R621C
mutant HA-Synphilin-1 were incubated with oleic acid (600 lM) in medium for 14 h. The cells were processed for double ﬂuorescence confocal
microscopy for HA-Synphilin-1 and lipid droplets using an anti-HA antibody and oil red O, respectively. Arrows represent co-localization of HA-
Synphilin-1 and lipid droplets. Bars, 10 lm.
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tected at the 32· dilution level, suggesting that the Synphilin-
1 C-terminus possesses capacity to bind to PA. In addition,
no binding between phospholipids, except PA and all GST-fu-
sion proteins other than GST-Syp-C, was detected (Fig. 1B).
GST-Syp-C also showed a high aﬃnity for PS at the 16· dilu-
tion level, as well as a low aﬃnity for CL and PG at the 2·
dilution level (Fig. 1B). GST-Syp-C did not interact with PC,
SM, PC, PI, or PE. All assays were replicated three times with
the same results. Accordingly, the C-terminus (aa 610–919)
confers phospholipid-binding capacity to Synphilin-1. The the-
oretical isoelectric point (pI) for other regions of Synphilin-1 is
lower than 7.4 (4.5 for Syp-N1, 4.9 for Syp-N2, and 5.3 for
Syp-ANK) and is thus unlikely to interact with acidic phos-
pholipids. On the other hand, the pI for Syp-C was 9.5, consis-tent with an aﬃnity to acidic phospholipids. The C-terminus
might represent a primary determinant of phospholipid-bind-
ing capacity.3.2. The C-terminus of Synphilin-1 interacts with multilamellar
vesicles containing PA and PS
Since the C-terminus of Synphilin-1 showed aﬃnity for PA
and PS, a pull-down assay was performed using MLVs con-
taining such phospholipids to conﬁrm the interaction. As a
control, MLVs containing PE were also subjected to the
assay. MLVs containing PA, PS, and PE were prepared using
their palmitoylated derivatives, i.e. 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphoethanolamine, 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphate, and 1-palmitoyl-2-oleoyl-sn-glycero-3-
T. Takahashi et al. / FEBS Letters 580 (2006) 4479–4484 4483[phospho-L-serine]. MLVs were ﬁrst incubated with GST-fu-
sion Synphilin-1 proteins, then bound proteins were analyzed
by immunoblotting with anti-GST antibodies. MLVs contain-
ing PA and PS, but not PE, precipitated GST-Syp-C (Fig. 2).
On the other hand, no MLVs precipitated GST alone or
GST-Syp-N1, -N2, or -ANK. No GST-fusion protein was
precipitated in the absence of MLVs (Fig. 2). Such selective
interaction agreed with the results of the protein–lipid overlay
assays.3.3. The primary determinant site for phospholipid binding
To identify the region responsible for phospholipid binding
within the C-terminus, GST-fusion proteins containing serial
C-terminal truncations, i.e. GST-Syp-C1, -C2, -C3, -C4, and
-C5, were generated (Fig. 3A). GST-Syp-C (Fig. 1B) and
GST-Syp-C1 (aa 610–675) showed similar binding to phospho-
lipids, including PA, PS, CL, and PG, while GST-Syp-C2 (aa
641–730) had a low binding aﬃnity to only PS. Such results
suggest that 30 amino acids (aa 610–640), which includes the
ankyrin repeat 5, represent the primary determinant site for
phospholipid binding. Interestingly, the R621C mutation
found in Parkinson’s disease also resides within this sequence.
It should also be noted that GST-Syp-C4 and -C5 also exhib-
ited binding aﬃnity to PS, CL, and PG (Fig. 3B). All assays
were replicated three times with the same results. Since the cal-
culated pI of aa 675–730 is 5.1, it is likely that the acidic nature
of this region inhibits phospholipid binding. However, such
phenomenon was not observed. Therefore, simple charge-
based interactions may not be the sole inﬂuence on in vitro
binding.3.4. Synphilin-1 was localized around lipid droplets
The R621C mutation in the Synphilin-1 protein has been re-
ported in Parkinson’s disease [5]. Moreover, amino acid resi-
due 621 localizes to the middle of the ankyrin repeat 5. To
investigate whether or not the R621C mutation in Synphilin-
1 aﬀects the phospholipid-binding speciﬁcity, a protein–lipid
overlay assay was performed using lysate proteins from
COS7 cells transfected with HA-tagged expression vectors
for wild type or R621C mutant Synphilin-1, as well as empty
expression vectors. At a time of 24 h post-transfection, pro-
teins in cell lysates (Fig. 4A) were incubated with the mem-
brane phospholipid array and bound proteins were detected
with immunoblotting with an anti-HA antibody. The
phospholipid-binding speciﬁcity of wild type Synphilin-1 was
similar to that of GST-Syp-C or GST-Syp-C1 (Fig. 4A). In
contrast, the R621C mutation inhibited Synphilin-1 binding
to PS (Fig. 4A), suggesting that a single amino acid substitu-
tion in the primary determinant site could change the
phospholipid-binding speciﬁcity.
Repeated immunoﬂuorescent staining revealed that wild
type Synphilin-1 preferentially localized around lipid droplets
(Fig. 4B). The appearance of Synphilin-1 localized to the vicin-
ity of lipid droplets was similar to previous descriptions,
namely a ring-like conﬁguration [9]. In contrast, R621C mu-
tant Synphilin-1 did not localize to the vicinity of lipid droplets
and both entities were independently distributed in the cyto-
plasm (Fig. 4B). It is noteworthy that a single substitution in
the Syp-C1 region abolished the ability of Synphlilin-1 to inter-
act with lipid droplets.3.5. Concluding remarks
A number of proteins with aﬃnity to phospholipids, such as
adipose diﬀerentiation-related protein perilipin or a-synuclein,
are present on the surface of lipid droplets that are coated by a
phospholipid monolayer originating from endoplasmic reticu-
lum [4,16]. In a previous study, we found that Synphilin-1
exhibits a ring-like conﬁguration in the cytoplasm [9]. Over-
expression of Synphilin-1 leads to formation of membrane-
bound inclusions that contain multi-layered or lamellar-like
phospholipid accumulations [17]. The core region of Lewy
bodies is immunolabeled intensely with anti-Synphilin-1 anti-
body [18] and enriched with lipids [19]. In addition, a-synuclein
immunoreactivity concentrates around lipid droplets, which
are a component of neuromelanin in the substantia nigra
[20]. Such ﬁndings indicate that the lipophilic properties of
both Synphilin-1 and a-synuclein may be relevant to not only
the pathogenesis of Parkinson’s disease, but also physiologic
function.
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